New antibody SM17 passes first safety check in healthy volunteers
NCT ID NCT07466940
First seen Mar 16, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This early-stage study tested a single dose of the experimental antibody SM17 in 30 healthy Chinese adults to see if it is safe and how the body processes it. The goal was not to treat any disease, but to gather important safety and drug-level information for future studies in conditions like eczema, asthma, and inflammatory bowel disease. Participants received either the drug or a placebo by injection and were monitored for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
PKUCare Luzhong Hospital
Zibo, Shandong, China
Conditions
Explore the condition pages connected to this study.